RAB9A

Across TCGA pan-cancer cohorts, RAB9A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RAB9A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RAB9A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RAB9A is over-expressed in tumor, although a few such as PDAC and LSCC show the opposite, repressed pattern.

CCRCC, PDAC, and HNSC are the cancer types where RAB9A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RAB9A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+0.334	<.001	9	view →
PDAC	Male	All	−0.398	<.001	6	view →
HNSC	All	II,III,IV	+0.130	.009	4	view →
LSCC	All	All	−0.116	<.001	4	view →
LUAD	All	II,III,IV	−0.090	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RAB9A–CCRCC

Open the CCRCC breakdown →